The Japan Times - Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

EUR -
AED 4.031682
AFN 70.803249
ALL 89.802128
AMD 395.791487
ANG 1.965511
AOA 1006.685892
ARS 1726.870351
AUD 1.647859
AWG 1.976046
AZN 1.858467
BAM 1.957982
BBD 2.209563
BDT 136.452074
BGN 1.946922
BHD 0.413961
BIF 3304.388048
BMD 1.097803
BND 1.415271
BOB 12.808275
BRL 6.52743
BSD 1.097023
BTN 101.610243
BWP 15.641789
BYN 3.293456
BYR 21516.948362
BZD 2.206359
CAD 1.572653
CDF 2502.992255
CHF 0.922643
CLF 0.028326
CLP 1114.753567
CNY 7.318672
CNH 7.326693
COP 3766.102689
CRC 491.047266
CUC 1.097803
CUP 26.329224
CVE 110.390543
CZK 24.456372
DJF 195.357724
DKK 7.474428
DOP 66.183459
DZD 150.504115
EGP 59.077532
ERN 16.467052
ETB 180.060475
FJD 2.515672
FKP 0.837136
GBP 0.837717
GEL 2.848766
GGP 0.837136
GHS 12.917396
GIP 0.837136
GMD 81.237618
GNF 9725.839323
GTQ 8.385307
GYD 229.523118
HKD 8.606203
HNL 29.487729
HRK 7.500155
HTG 143.859675
HUF 372.335413
IDR 20049.898671
ILS 3.657574
IMP 0.837136
INR 101.678724
IQD 1663.14598
IRR 2126790.622064
ISK 137.159344
JEP 0.837136
JMD 173.78368
JOD 0.778349
JPY 174.434939
KES 142.791531
KGS 96.003038
KHR 4475.968023
KMF 492.914079
KPW 988.023523
KRW 1469.607173
KWD 0.342284
KYD 0.914219
KZT 500.42772
LAK 24730.561893
LBP 98244.492223
LKR 364.836606
LRD 183.754792
LSL 19.176785
LTL 3.241529
LVL 0.66405
LYD 7.097911
MAD 10.970727
MDL 20.108869
MGA 4971.540718
MKD 61.522411
MMK 2305.175661
MNT 3959.954055
MOP 8.857031
MRU 44.716836
MUR 51.35511
MVR 16.917044
MWK 1902.320111
MXN 20.832347
MYR 4.515156
MZN 70.160892
NAD 19.176785
NGN 1489.620919
NIO 40.374997
NOK 10.703782
NPR 162.575448
NZD 1.99865
OMR 0.422093
PAB 1.097023
PEN 3.765797
PGK 4.938616
PHP 70.070632
PKR 303.25137
PLN 4.451862
PYG 6917.930501
QAR 4.010297
RON 5.348612
RSD 117.617537
RUB 89.829785
RWF 1620.706256
SAR 4.122619
SBD 8.925822
SCR 15.324676
SDG 660.327047
SEK 11.203798
SGD 1.415563
SHP 0.834959
SLE 25.025569
SLL 23020.394262
SOS 626.995923
SRD 41.017786
STD 22722.315742
STN 24.527224
SVC 9.598698
SYP 14273.641319
SZL 19.172979
THB 37.213311
TJS 10.087664
TMT 3.85329
TND 3.322903
TOP 2.643248
TRY 55.524483
TTD 7.446299
TWD 36.131996
TZS 2929.082599
UAH 49.269732
UGX 4635.165833
USD 1.097803
UYU 44.609717
UZS 13133.63727
VES 1007.363967
VND 28324.976692
VUV 133.003489
WST 3.099409
XAF 655.957
XAG 0.025995
XAU 0.000307581213
XCD 2.966868
XCG 1.977204
XDR 0.776204
XOF 655.957
XPF 119.331742
YER 259.684967
ZAR 19.134018
ZMK 9881.548488
ZMW 22.588174
ZWL 353.492275
SSP 6348.208095
MXV 2.33524
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.

Text size:

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.

As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.

Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."

Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."

André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."

About MEndoB

Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.

About Micreos

Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.

For more information, visit www.micreos.com.

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.

For more information, please visit www.northwaybiotech.com.

Micreos Contact:

Matt Regan
CEO and Board member, Micreos Pharmaceutical AG
[email protected]

Northway Biotech Contact:

Vladas Algirdas Bumelis
CEO and Chairman of the Board
[email protected]

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
[email protected]

SOURCE: Northway Biotech



View the original press release on ACCESS Newswire

Y.Kimura--JT